These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38708718)

  • 1. WDR61 ablation triggers R-loop accumulation and suppresses breast cancer progression.
    Hou Y; Zhang C; Liu L; Yu Y; Shi L; Qin Y
    FEBS J; 2024 Aug; 291(15):3417-3431. PubMed ID: 38708718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability.
    Fagan-Solis KD; Simpson DA; Kumar RJ; Martelotto LG; Mose LE; Rashid NU; Ho AY; Powell SN; Wen YH; Parker JS; Reis-Filho JS; Petrini JHJ; Gupta GP
    Cell Rep; 2020 Feb; 30(5):1385-1399.e7. PubMed ID: 32023457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway.
    Cheradame L; Guerrera IC; Gaston J; Schmitt A; Jung V; Goudin N; Pouillard M; Radosevic-Robin N; Modesti M; Judde JG; Cairo S; Goffin V
    Oncogene; 2021 Dec; 40(49):6627-6640. PubMed ID: 34625708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.
    D'Assoro AB; Leontovich A; Amato A; Ayers-Ringler JR; Quatraro C; Hafner K; Jenkins RB; Libra M; Ingle J; Stivala F; Galanis E; Salisbury JL
    Int J Oncol; 2010 Nov; 37(5):1167-76. PubMed ID: 20878064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
    Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
    Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clusterin, a Novel DEC1 Target, Modulates DNA Damage-Mediated Cell Death.
    Ming X; Bao C; Hong T; Yang Y; Chen X; Jung YS; Qian Y
    Mol Cancer Res; 2018 Nov; 16(11):1641-1651. PubMed ID: 30002194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GNA13 suppresses proliferation of ER+ breast cancer cells via ERα dependent upregulation of the MYC oncogene.
    Subramanyan LV; Rasheed SAK; Wang L; Ghosh S; Ong MSN; Lakshmanan M; Wang M; Casey PJ
    Breast Cancer Res; 2024 Jul; 26(1):113. PubMed ID: 38965558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TFPI2 suppresses breast cancer progression through inhibiting TWIST-integrin α5 pathway.
    Zhao D; Qiao J; He H; Song J; Zhao S; Yu J
    Mol Med; 2020 Apr; 26(1):27. PubMed ID: 32248791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of TRIM31 promotes breast cancer progression through regulating K48- and K63-linked ubiquitination of p53.
    Guo Y; Li Q; Zhao G; Zhang J; Yuan H; Feng T; Ou D; Gu R; Li S; Li K; Lin P
    Cell Death Dis; 2021 Oct; 12(10):945. PubMed ID: 34650049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Function of RasGRP3 in the formation and progression of human breast cancer.
    Nagy Z; Kovács I; Török M; Tóth D; Vereb G; Buzás K; Juhász I; Blumberg PM; Bíró T; Czifra G
    Mol Cancer; 2014 Apr; 13():96. PubMed ID: 24779681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotically-Associated lncRNA (MANCR) Affects Genomic Stability and Cell Division in Aggressive Breast Cancer.
    Tracy KM; Tye CE; Ghule PN; Malaby HLH; Stumpff J; Stein JL; Stein GS; Lian JB
    Mol Cancer Res; 2018 Apr; 16(4):587-598. PubMed ID: 29378907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
    Chu W; Zhang X; Qi L; Fu Y; Wang P; Zhao W; Du J; Zhang J; Zhan J; Wang Y; Zhu WG; Yu Y; Zhang H
    Cancer Res; 2020 Jul; 80(13):2737-2750. PubMed ID: 32312833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
    Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
    J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
    Padró M; Louie RJ; Lananna BV; Krieg AJ; Timmerman LA; Chan DA
    BMC Cancer; 2017 Mar; 17(1):203. PubMed ID: 28320353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of lncRNA PANDAR reduces cell proliferation, cell invasion and suppresses EMT pathway in breast cancer.
    Li Y; Su X; Pan H
    Cancer Biomark; 2019; 25(2):185-192. PubMed ID: 31104011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer.
    Katara GK; Kulshrestha A; Schneiderman S; Riehl V; Ibrahim S; Beaman KD
    Mol Oncol; 2020 Jan; 14(1):211-224. PubMed ID: 31725949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells.
    Krishnan R; Lapierre M; Gautreau B; Nixon KCJ; El Ghamrasni S; Patel PS; Hao J; Yerlici VT; Guturi KKN; St-Germain J; Mateo F; Saad A; Algouneh A; Earnshaw R; Shili D; Seitova A; Miller J; Khosraviani N; Penn A; Ho B; Sanchez O; Hande MP; Masson JY; Brown GW; Alaoui-Jamali M; Reynolds JJ; Arrowsmith C; Raught B; Pujana MA; Mekhail K; Stewart GS; Hakem A; Hakem R
    Nucleic Acids Res; 2023 Oct; 51(19):10484-10505. PubMed ID: 37697435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
    Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
    Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEIS2 suppresses breast cancer development by downregulating IL10.
    Xiao Y; Liu Y; Sun Y; Huang C; Zhong S
    Cancer Rep (Hoboken); 2024 May; 7(5):e2064. PubMed ID: 38711262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.